Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2negative Breast Cancers

被引：0
|
作者：
Luzhna, Lidiya
Chia, Stephen
Pauls, Mehrnoosh
Levasseur, Nathalie
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-15-04
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Incidence of HER2-low Expression in HR-positive/HER2-negative and Triple-Negative Breast Cancers in the Integra Connect Database
    Fares, Marielle
    Gart, Mike
    Blanc, Simon
    Zheng, Jia
    Saunders, William
    Smith, Robert
    Vasudevan, Anupama
    English, Sandy
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [23] EU-Approval for Ibrance for Therapy of Patients with HR-positive/HER2-negative Breast Cancer
    Janik, Achim
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 67 - 67
  • [24] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [25] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2017, 97 : 56A - 57A
  • [26] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    MODERN PATHOLOGY, 2017, 30 : 56A - 57A
  • [27] Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negative advanced breast cancer
    Song, Xifu
    Lu, Jingjing
    Wang, Liyan
    Kong, Feifei
    Yuan, Hangyu
    Chen, Cheng
    Shan, Haixia
    JOURNAL OF BUON, 2020, 25 (05): : 2228 - 2236
  • [28] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA
    Berdunov, V
    Richardson, R.
    Millen, S.
    VALUE IN HEALTH, 2022, 25 (07) : S371 - S371
  • [29] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR HR+/HER2-EARLY-STAGE BREAST CANCER IN THE US
    Berdunov, V
    Carter, Cuyun G.
    Laws, E.
    Luo, R.
    Russell, C.
    Campbell, S.
    Force, J.
    Abdou, Y. G.
    VALUE IN HEALTH, 2022, 25 (07) : S352 - S353
  • [30] Neoadjuvant letrozole plus palbociclib in patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) with baseline Ki67 ≥20% and an Oncotype DX Breast Recurrence Score® result (RS) ≥18: DxCARTES
    Llombart-Cussac, Antonio
    Guerrero-Zotano, Angel
    Ruiz, Manuel
    Bermejo, Begona
    Gil-Gil, Miguel
    de la Haba, Juan
    Alba, Emilio
    Quiroga, Vanesa
    Caranana, Vicente
    Urruticoechea, Ander
    Morales, Serafin
    Bellet, Meritxell
    Anton, Antonio
    Perez-Garcia, Jose Manuel
    Fernandez-Abad, Maria
    Servitja, Sonia
    Sanchez-Rovira, Pedro
    Braga, Sofia
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
12345